Accretion Nutraveda Ltd vs Advanced Enzyme Technologies Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Accretion Nutraveda Ltd is ₹ 274.7 as of 12 May 15:30 . The P/E Ratio of Accretion Nutraveda Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Advanced Enzyme Technologies Ltd changed from 26.4 on March 2021 to 23.8 on March 2025 . This represents a CAGR of -2.05% over 5 years The Market Cap of Accretion Nutraveda Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Advanced Enzyme Technologies Ltd changed from ₹ 3852 crore on March 2021 to ₹ 3120 crore on March 2025 . This represents a CAGR of -4.13% over 5 years The revenue of Accretion Nutraveda Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Advanced Enzyme Technologies Ltd for the Mar '26 is ₹ 210.71 crore as compare to the Dec '25 revenue of ₹ 191.66 crore. This represent the growth of 9.94% The ebitda of Accretion Nutraveda Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Advanced Enzyme Technologies Ltd for the Mar '26 is ₹ 70.57 crore as compare to the Dec '25 ebitda of ₹ 69.07 crore. This represent the growth of 2.17% The net profit of Accretion Nutraveda Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Advanced Enzyme Technologies Ltd changed from ₹ 34.98 crore to ₹ 45.25 crore over 8 quarters. This represents a CAGR of 13.74% The Dividend Payout of Accretion Nutraveda Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Advanced Enzyme Technologies Ltd changed from 14.16 % on March 2021 to 56.81 % on March 2025 . This represents a CAGR of 32.03% over 5 years .

About Accretion Nutraveda Ltd

Accretion Nutraveda Limited was initially incorporated as a Private Limited Company on March 16, 2021 and has subsequently, converted the status into a Public Limited Company vide Certificate of Incorporation issued by the Registrar of Companies, Central Processing Centre w.e.f.
May 2, 2025. The Company, established at Ahmedabad, is a healthcare-focused Contract Development and Manufacturing Organization (CDMO), offering specialized services to a diverse range of clients across the various industries.
It specialize in ayurvedic and nutraceutical products including Tablets, Capsules, Oral Liquids, Oral Powders, External Preparation and Oils.
Apart from these, it offer a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science. The products include Tablets, such as film-coated and chewable varieties, for applications in liver care, gynecological care, bone and joint health, and respiratory support.

About Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Limited (AETL) is largest Indian enzyme company that transformed business globally in the manufacturing and sale of enzymes.
The Company was incorporated, as a Private Company on March 15, 1989 as 'Advanced Biochemicals Private Limited' in Maharashtra.
It thereafter converted the status into a Public Company and the name of the Company was changed to Advanced Biochemicals Limited on May 28, 1992 and further was changed to Advanced Enzyme Technologies Limited via fresh Certificate of Incorporation at RoC, Mumbai on August 19, 2005. In 2011, the company took over Cal-India Foods International, giving the company direct presence in USA. In 2012, the company took over Advanced Supplementary Technologies Corporation for consolidating its presence in USA. Advanced Enzyme Technologies Limited came out with its Initial Public Offer (IPO) of 4,594,875 Equity shares of Rs 10 each at an issue price of Rs 896 per Equity share ( Rs 810 per Equity share for eligible employees), consisting of fresh issue of 560,405 Equity shares and an Offer for Sale of 4,034,470 Equity shares by Selling Shareholders.

FAQs for the comparison of Accretion Nutraveda Ltd and Advanced Enzyme Technologies Ltd

Which company has a larger market capitalization, Accretion Nutraveda Ltd or Advanced Enzyme Technologies Ltd?

Market cap of Accretion Nutraveda Ltd is 198 Cr while Market cap of Advanced Enzyme Technologies Ltd is 4,140 Cr

What are the key factors driving the stock performance of Accretion Nutraveda Ltd and Advanced Enzyme Technologies Ltd?

The stock performance of Accretion Nutraveda Ltd and Advanced Enzyme Technologies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Accretion Nutraveda Ltd and Advanced Enzyme Technologies Ltd?

As of May 12, 2026, the Accretion Nutraveda Ltd stock price is INR ₹274.7. On the other hand, Advanced Enzyme Technologies Ltd stock price is INR ₹369.75.

How do dividend payouts of Accretion Nutraveda Ltd and Advanced Enzyme Technologies Ltd compare?

To compare the dividend payouts of Accretion Nutraveda Ltd and Advanced Enzyme Technologies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.